A mutated cathepsin-D devoid of its catalytic activity stimulates the growth of cancer cells.
Cathepsin-D, a lysosomal aspartyl proteinase, is highly secreted by breast cancer cells and its over-expression by transfection stimulates cancer cell proliferation. The mechanism by which this protease affects proliferation remains, however, unknown. In order to determine whether proteolytic activity is necessary, we abolished its enzymatic activity using site-directed mutagenesis followed by stable transfection in 3Y1-Ad12 cancer cells. Substitution of the aspartic acid residue 231 by an asparagine residue in its catalytic site abrogated the cathepsin-D proteolytic activity but did not affect its expression level, processing or secretion. However, like wild-type cathepsin-D, this mutated catalytically-inactive cathepsin-D retained its capacity to stimulate proliferation of cells embedded in Matrigel or collagen I matrices, colony formation in soft agar and tumor growth in athymic nude mice. Addition on the mock-transfected cells, of either conditioned media containing the wild-type or the mutated pro-cathepsin-D, or of the purified mutated pro-cathepsin-D, partially mimicked the mitogenic activity of the transfected cathepsin-D, indicating a role of the secreted pro-enzyme. Moreover, addition of two anti-cathepsin-D antibodies on the cathepsin-D transfected cells inhibited their proliferation, suggesting an action of the secreted pro-cathepsin-D via an autocrine loop. A synthetic peptide containing the 27-44 residue moiety of the cathepsin-D pro-fragment was, however, not mitogenic suggesting that a receptor for the pro-fragment was not involved. Furthermore, the cathepsin-D mitogenicity was not blocked by inhibiting the interaction of pro-cathepsin-D with the mannose-6-phosphate receptors. Our results altogether demonstrate that a mutated cathepsin-D devoid of catalytic activity is still mitogenic and suggest that it is acting extra-cellularly by triggering directly or indirectly a yet unidentified cell surface receptor.
Glondu
M
M
INSERM U540 Endocrinologie Moléculaire et Cellulaire des Cancers, Université de Montpellier 1, 60 rue de Navacelles, 34090 Montpellier, France.
Coopman
P
P
Laurent-Matha
V
V
Garcia
M
M
Rochefort
H
H
Liaudet-Coopman
E
E
D000818:Animals; D000906:Antibodies / Q000276:immunology; D001943:Breast Neoplasms / Q000201:enzymology* / Q000473:pathology*; D002384:Catalysis; D002402:Cathepsin D / Q000235:genetics* / Q000276:immunology / Q000494:pharmacology / Q000502:physiology*; D002455:Cell Division; D004792:Enzyme Precursors / Q000494:pharmacology; D005260:Female; D007700:Kinetics; D051379:Mice; D008819:Mice, Nude; D008934:Mitogens / Q000235:genetics / Q000502:physiology; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D051381:Rats; D017527:Receptor, IGF Type 2 / Q000378:metabolism; D014162:Transfection; D014407:Tumor Cells, Cultured
D000906:Antibodies; D004792:Enzyme Precursors; D008934:Mitogens; D017527:Receptor, IGF Type 2; C058345:procathepsin D; D002402:Cathepsin D